FDA Updates Week of April 8: Fasenra Gets New Indication
In a slow week, the FDA has approved Fasenra for children 6 to 11 years of age with eosinophilic asthma, a rare form of asthma.
Fasenra Approved for Children with Severe Asthma
The FDA has approved AstraZeneca’s Fasenra (benralizumab) as an add-on maintenance treatment for children aged 6 to 11 with eosinophilic asthma. Fasenra was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma in patients aged 12 and older.
Eosinophilic asthma is a rare type of asthma where white blood cells called eosinophils are elevated, causing inflammation. Fasenra is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and leads to depletion of blood and tissue eosinophils.
This additional indication was supported by evidence from TATE, an open-label, phase 3 trial, as well as trials in adult and adolescent populations. In the TATE study, Fasenra met the primary endpoints, demonstrating pharmacokinetics and pharmacodynamics in the younger patient population that were consistent with those seen in prior trials.
The recommended dose is 30 mg for patients 6 years and older who weigh 35 kg or more. For patients aged 6 to 11 who weigh less than 35 kg, a new 10 mg dose will be available. Fasenra is administered by subcutaneous injection every four weeks for the first three doses, and then every eight weeks.
The list price for Fasenra is $5,511.41 per 30 mg dose. AstraZeneca says for people with employer or individual private insurance, the average out-of-pocket cost is $46 per dose. Some patients may pay as little as $0 for Fasenra and as little as $0 for its injection administration. For people with Medicare Advantage plans, the average out-of-pocket cost is $90 per dose
FDA Lifts Safety Restrictions on CAR T Therapies After Reviewing Real-World Data
July 2nd 2025FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine release syndrome and neurological toxicities.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
